Evaluation of Safety and Efficacy of DUR-928 in Subjects with AH

• Research type

  Research Study

• Full title

  A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis.

• IRAS ID

  291351

• Contact name

  Debbie Shawcross

• Contact email

  debbie.shawcross@kcl.ac.uk

• Sponsor organisation

  DURECT Corporation

• Eudract number

  2020-004534-38

• ISRCTN Number

  ISRCTN00000000

• Clinicaltrials.gov Identifier

  NCT04563026

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  2 years, 4 months, days

• Research summary

  This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  21/NW/0206

• Date of REC Opinion

  23 Aug 2021

• REC opinion

  Further Information Favourable Opinion